Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 154, Issue 4, 2010, Pages 463-468

  Laje, Gonzalo ^a   Bernert, Rebecca ^b   Morse, Rebecca ^c   Pao, Maryland ^a   Smith, Ann C M ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Aggression; Autism; Genetics; Melatonin; Mental retardation; Pharmacogenetics; Pharmacogenomics; Pharmacology; Self injurious behavior; Sleep; Smith Magenis syndrome (SMS); Treatment

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORAL HYDRATE; CLONIDINE; DIPHENHYDRAMINE; GUANFACINE; MELATONIN; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MOOD STABILIZER; NEUROLEPTIC AGENT; PEMOLINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZOLPIDEM;

AGE DISTRIBUTION; ARTICLE; CAREGIVER; CHILD; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SMITH MAGENIS SYNDROME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; FEMALE; HUMANS; MALE; PSYCHOTROPIC DRUGS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SMITH-MAGENIS SYNDROME; TREATMENT OUTCOME;

EID: 78049364470     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30282     Document Type: Article

References (18)

1. Carpizo R, Martinez A, Mediavilla D, Gonzalez M, Abad A, Sanchez-Barcelo EJ. 2006. Smith-Magenis syndrome: A case report of improved sleep after treatment with beta1-adrenergic antagonists and melatonin. J Pediatr 149:409-411.
2. De Leersnyder H, De Blois MC, Claustrat B, Romana S, Albrecht U, Von Kleist-Retzow JC, Delobel B, Viot G, Lyonnet S, Vekemans M, et al. 2001a. Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. J Pediatr 139:111-116.
3. De Leersnyder H, de Blois MC, Vekemans M, Sidi D, Villain E, Kindermans C, Munnich A. 2001b. Beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. J Med Genet 38:586-590.
4. De Leersnyder H, Bresson JL, de Blois MC, Souberbielle JC, Mogenet A, Delhotal-Landes B, Salefranque F, Munnich A. 2003. Beta 1-adrenergic antagonists and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. J Med Genet 40:74-78.
5. Duncan W, Gropman A, Morse R, Krasnewich D, Smith ACM. 2003. Good babies sleeping poorly: Insufficient sleep in infants with Smith-Magenis syndrome (SMS). Am J Hum Genet 73:A896.
6. Dykens EM, Smith AC. 1998. Distinctiveness and correlates of maladaptive behaviour in children and adolescents with Smith-Magenis syndrome. J Intellect Disabil Res 42:481-489.
7. Dykens EM, Finucane BM, Gayley C. 1997. Brief report: Cognitive and behavioral profiles in persons with Smith-Magenis syndrome. J Autism Dev Disord 27:203-211.
8. Finucane BM, Konar D, Haas-Givler B, Kurtz MB, Scott CI Jr. 1994. The spasmodic upper-body squeeze: A characteristic behavior in Smith-Magenis syndrome. Dev Med Child Neurol 36:78-83.
9. Finucane B, Dirrigl KH, Simon EW. 2001. Characterization of self-injurious behaviors in children and adults with Smith-Magenis syndrome. Am J Ment Retard 106:52-58.
10. Greenberg F, Guzzetta V, Montes de Oca-Luna R, Magenis RE, Smith AC, Richter SF, Kondo I, Dobyns WB, Patel PI, Lupski JR. 1991. Molecular analysis of the Smith-Magenis syndrome: A possible contiguous-gene syndrome associated with del(17)(p11. 2). Am J Hum Genet 49:1207-1218.
11. Greenberg F, Lewis RA, Potocki L, Glaze D, Parke J, Killian J, Murphy MA, Williamson D, Brown F, Dutton R, et al. 1996. Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). Am J Med Genet 62:247-254.
12. Gropman AL, Duncan WC, Smith AC. 2006. Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2). Pediatr Neurol 34:337-350.
13. Laje G, Morse R, Richter W, Ball J, Pao M, Smith ACM. 2010. Autism spectrum features in Smith-Magenis syndrome. Am J Med Genet Part C; in press.
14. Martin SC, Wolters PL, Smith AC. 2006. Adaptive and maladaptive behavior in children with Smith-Magenis syndrome. J Autism Dev Disord 36:541-552.
15. Niederhofer H. 2007. Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2). Psychiatr Danub 19:189-192.
16. Potocki L, Glaze D, Tan DX, Park SS, Kashork CD, Shaffer LG, Reiter RJ, Lupski JR. 2000. Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet 37:428-433.
17. Smith AC, Dykens E, Greenberg F. 1998a. Behavioral phenotype of Smith-Magenis syndrome (del 17p11.2). Am J Med Genet 81:179-185.
18. Smith AC, Dykens E, Greenberg F. 1998b. Sleep disturbance in Smith-Magenis syndrome (del 17 p11.2). Am J Med Genet 81:186-191.